Technology News and Research

RSS

MedClean Technologies signs Partnership Agreement with Bear Consulting

MedClean Technologies, the leading provider of on-site technology for the treatment and disposal of medical waste and the destruction of confidential documents and related media, today announced it has signed a Partnership Agreement with Bear Consulting aimed at implementing an expense reduction program that could save the Federal Government more than $100 million over the next decade.

7 Jul 2010

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.

7 Jul 2010

Molecular Templates enters into oncology drug discovery and translation research agreement with ImClone

Molecular Templates announced today that it has entered into a collaborative oncology drug discovery and translation research agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.

7 Jul 2010

Retin-A Micro Pump combines tretinoin for treating acne: Study

From the minute they wake until the minute they sleep, today's teenagers have busy, demanding schedules. Life may be hectic, but an acne care routine doesn't have to get in the way, according to a new study published in the July 2010 issue of Journal of Drugs in Dermatology.

7 Jul 2010

Dehaier Medical Systems reaffirms earlier earnings estimate for fiscal 2010

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today reaffirmed the company's earlier earnings estimate of $0.80 EPS for fiscal year 2010.

7 Jul 2010

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the company will pursue a Phase 3 clinical program for its autologous cell therapy for the treatment of critical limb ischemia (CLI) through the U.S. Food and Drug Administration's special protocol assessment (SPA) process. Aastrom is currently completing a Phase 2b clinical trial of its cell therapy in patients with CLI and recently met with FDA officials to discuss plans for the Phase 3 program.

7 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

Cymetrix announces expanded partnership with Torrance Memorial Medical Center

Cymetrix, a leader in providing hospitals and healthcare networks with revenue cycle management solutions, today announced an expanded partnership with Torrance Memorial Medical Center to provide self-pay accounts receivable management services. Cymetrix's outstanding performance, and its ability to help the medical center increase its payments from managed care organizations during an earlier contract, contributed to Torrance Memorial's decision to expand its partnership.

7 Jul 2010

PhyloTech closes $1.2M Seed financing round

PhyloTech, Inc., announced today it closed a $1.2 M Seed financing round in June. The Company provides analysis of over 50,000 bacterial and archaeal taxa in samples from any source to solve problems in human health, environmental damages assessment, bioremediation, recreational water quality, drinking water and food safety, and an array of other applications.

7 Jul 2010

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.

7 Jul 2010

Dell hedging on health IT investment; Privacy concerns remain

The Wall Street Journal: Dell is hoping to capitalize on its purchase of health technology firm Perot Systems by providing services to new clients such as the 2,600-doctor Methodist Hospital System in Houston. Dell has contracted to create an electronic medical records system for Methodist, a new foray into IT services for the hardware-focused firm.

7 Jul 2010

Hologic enters definitive agreement to acquire Sentinelle Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that it has entered into a definitive agreement to acquire Sentinelle Medical Inc., a leading provider of Magnetic Resonance Imaging (MRI) breast coils, tables and visualization software.

From Hologic, Inc. 7 Jul 2010

Biomagnetics Diagnostics signs new CRADA with Los Alamos National Security

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of a new Cooperative Research and Development Agreement with Los Alamos National Security, LLC for the development of a waveguide-based integrated optical biosensor platform for the detection of disease causing pathogens.

7 Jul 2010

Emergency room visits increase in Mass., plus more hospital news

The Boston Globe: In Massachusetts, "[t]he number of people visiting hospital emergency rooms has climbed … despite the enactment of nearly universal health insurance that some hoped would reduce expensive emergency department use. According to state data released last week, emergency room visits rose by 9 percent from 2004 to 2008, to about 3 million visits a year.

7 Jul 2010

St. Jude Medical acquires LightLab Imaging

St. Jude Medical, Inc., a global medical device company, today completed the previously announced acquisition of LightLab Imaging, Inc. for approximately $90 million in cash.

7 Jul 2010

Alcon signs definitive agreement to acquire LenSx Lasers

Alcon, Inc. announced today that it has entered into a definitive agreement to acquire LenSx Lasers, Inc, a privately held company that developed the first femtosecond laser to receive U.S. Food and Drug Administration clearance for use as a part of cataract surgery. The LenSx system is indicated for anterior capsulotomy and laser phacofragmentation during cataract surgery, providing a complementary surgical approach to certain manual steps within the traditional cataract procedure.

7 Jul 2010

Payroll woes may spread to other systems if incorporated: Auditor General’s report

There have been massive errors in the newly introduced payroll system of the Queensland health care staff since March this year. It left many workers under, over or un-paid for weeks.

6 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.

6 Jul 2010

BioNeutral, KRP complete manufacturing and distribution agreement

BioNeutral Group Inc., a specialty chemical technology-based life science company, announced today that it completed an agreement with Keystone Research and Pharmaceuticals for its proprietary formulations for use in the Veterinary, Dental and Cosmetic markets. The Terms are being held confidential.

6 Jul 2010